Selected recent publications:

➤ Robert G. Mannino, Eric J. Nehl, Sarah Farmer, Amanda Foster Peagler, Maren C. Parsell, Viviana Claveria, David Ku, David S. Gottfried, Hang Chen, Wilbur A. Lam, and Oliver Brand, “The critical role of engineering in the rapid development of COVID-19 diagnostics: Lessons from the RADx Tech Test Verification Core” Science Advances. 9, eade4962 (2023). https://www.science.org/doi/10.1126/sciadv.ade4962

➤ Liu ZL, Bresette C, Aidun CK, Ku DN. (2021) SIPA in 10 milliseconds: VWF tentacles agglomerate and capture platelets under high shear. Blood Advances doi.org/10.1182/bloodadvances.2021005692

➤ Kim DJ, Ku DN. “Structure of shear-induced platelet aggregated clot formed in an in vitro arterial thrombosis model” Blood Adv (2022) 6 (9): 2872–2883. doi.org/10.1182/bloodadvances.2021006248

➤ Kim DJ, Bressette C, Liu Z, Ku DN. Occlusive thrombosis in arteries.  APL Bioengineering  2019;3, 041502. https://doi.org/10.1063/1.5115554

Licensed Patents: 

➤ Ku, D.N., Wootton, D.M., Greer-Braddon, L., “Poly(vinyl Alcohol) Cryogel,” No. 5,981,826 and 6,231,605, issued May 15, 2001. Licensed; created prosthetic cartilage; acquired by Wright Medical. $645 million

➤ Denoziere, G., Ku, D.N., “Methods of Producing PVA Hydrogel Implants and Related Devices,” issued U.S. Patent No. 8,038,920, Licensed to Mimedx.  Market cap >$600 million.

Itamar Kolvin received his B.Sc. (2007) in Physics and Mathematics and his M.Sc. (2009) from the Hebrew University in Jerusalem. In 2017, he completed his Ph.D. in Physics under Prof. Jay Fineberg in the Hebrew University. He was a HFSP cross-disciplinary postdoctoral fellow in the Physics Department, University of California, Santa Barbara with Pro. Zvonimir Dogic. His research interests are in the fundamentals of soft matter out-of-equilibrium: assembly, deformation, flow and fracture. Current efforts make use of model systems that are assembled of protein machineries to investigate active and adaptive material mechanics. 

Kim joined the Woodruff School of Mechanical Engineering as an Assistant Professor in July 2013. Prior to his current appointment, he was a Postdoctoral Associate in the David H. Koch Institute for Integrative Cancer Research at MIT, where he developed biomimetic microsystems for probing nanoparticle behaviors in the inflamed endothelium and for synthesizing therapeutic and diagnostic nanomaterials. His doctorate research at CMU focused on closed-loop microfluidic control systems for lab-on-a-chip applications to biochemistry and developmental biology. Prior to his Ph.D., he was a researcher in areas of dynamics, controls, and robotics at R&D Divisions of Hyundai-Kia Motors and Samsung Electronics for six years.

Mijin Kim is an assistant professor in the School of Chemistry and Biochemistry at Georgia Tech. Her research program is focused on the development and implementation of novel nanosensor technology to improve cancer research and diagnosis. The Kim Lab combines nanoscale engineering, fluorescence spectroscopy, machine learning approaches, and biochemical tools (1) to understand the exciton photophysics in low-dimensional nanomaterials, (2) to develop diagnostic/nano-omics sensor technology for early disease detection, and (3) to investigate biological processes with focusing problems in lysosome biology and autophagy. For her scientific innovation, Kim has received multiple recognitions, including being named as one of the STAT Wunderkinds and the MIT Technology Review Innovators Under 35 List.

Yonggang Ke's research is highly interdisciplinary combining chemistry, biology, physics, material science, and engineering. The overall mission of his research is to use interdisciplinary research tools to program nucleic-acid-based "beautiful structures and smart devices" at nanoscale, and use them for scientific exploration and technological applications. Specifically, his team focuses on (1) developing new DNA self-assembly paradigms for constructing DNA nanostructures with greater structural complexity, and with controllable sizes and shapes; (2) developing new imaging or drug delivery systems based on DNA nanostructuresl; (3) exploring design of novel DNA-based nanodevices for understanding basic biological questions at molecular level; (4) developing DNA-templated protein devices for constructing artificial bio-reactors.

For cancer-related research/application, Ke will focus on using DNA/RNA nanostructures as drug delivery vehicles. He is also interested in using DNA/RNA nanostructures to study cancer cell biology at molecular level.

Dr. Yuhang Hu Joined the Woodruff School of Mechanical Engineering and the School of Chemical and Biomolecular Engineering at Georgia Institute of Technology as an assistant professor in August 2018. Prior to that, Dr. Hu was an assistant professor in the Department of Mechanical Science and Engineering at University of Illinois at Urbana-Champaign from 2015 to 2018. She received her Ph.D. from Harvard University in the area of Solid Mechanics. She worked in the area of Materials Chemistry as a post-doctoral fellow at Harvard from 2011 to 2014.

I am the Patsy and Alan Dorris Chair of Pediatric Technology and Professor of Biomedical Engineering at the Georgia Institute of Technology. I also direct the Center for 3D Medical Fabrication (3DMedFab) and the Tissue Engineering and Mechanics Laboratory at Georgia Tech. We develop a range of 3D printed medical devices. We have over 25 devices implanted in patients for treatment of trachecobronchomalacia.

Dr. Hekman completed her BA in Biophysics and Spanish Literature at Johns Hopkins. She then chose to pursue medicine and completed her MD and PhD in Molecular Medicine at the University of Chicago, where she found Vascular Surgery. She completed her Vascular Surgery Integrated Residency at Northwestern University, including a post-doctoral research fellowship in the lab of Dr. Jason Wertheim, MD, PhD. There she discovered the role of autophagy in the longevity and health of endothelial cells derived from induced pluripotent stem cells. She joined faculty in Vascular Surgery at Emory and the Atlanta VA Healthcare System in 2021, where her lab focuses on generating patient-specific induced pluripotent stem cell-derived endothelial cells to produce personalized regenerative therapies for vascular disease.

Robert E. Guldberg is the DeArmond Executive Director of the Phil and Penny Knight Campus for Accelerating Scientific Impact and Vice President of the University of Oregon. Guldberg’s research is focused on musculoskeletal mechanobiology, regenerative medicine, and orthopaedic medical devices. Over his 25+ year academic career, Dr. Guldberg has produced over 280 peer-reviewed publications, served as an advisor and board member for numerous biotechnology companies, and co-founded six start-ups. He was previously executive director of the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech from 2009-2018. In 2018, he was selected from a national search to lead the Knight Campus as its inaugural permanent Executive Director, where he has led the creation of its strategic plan, hired faculty into the campus’ first building opened in 2020, and launched the University of Oregon’s first ever engineering degree program. In 2021, he led the launch of Phase 2 of the Knight Campus development with the announcement of a second $500 million gift from Phil and Penny Knight. At the national level, Dr. Guldberg is past Chair of the Americas Chapter of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-AM). He currently serves on the Executive Leadership Council of the Wu Tsai Human Performance Alliance, a $220 million global initiative to promote wellness and peak performance through scientific discovery and innovation. Dr. Guldberg is an elected fellow of TERMIS, the American Society of Mechanical Engineers (ASME), the American Institute for Medical and Biological Engineering (AIMBE), the Orthopaedic Research Society (ORS), and the National Academy of Inventors (NAI).

Faces of Research - Profile Article